Simulations Plus Partners with ETC to Boost GastroPlus Functionality

Transforming Drug Development with a Strategic Collaboration

Simulations Plus, Inc. (Nasdaq: SLP), a leader in biosimulation technologies, recently embarked on an exciting journey toward innovation by forming a strategic alliance with the Enabling Technologies Consortium (ETC). This collaboration is set to significantly improve techniques in oral drug delivery, focusing on enhancing in vitro-in vivo correlation (IVIVC) methodologies, which are essential for developing effective medications.

Advancing GastroPlus through Enhanced Predictive Capabilities

The focus of this partnership is on refining the predictive capabilities of the GastroPlus platform. The advanced compartmental absorption and transit (ACAT™) model will receive an upgrade, aimed specifically at assisting developers of immediate release (IR) oral drug products. By leveraging data sourced from public repositories and ETC members, Simulations Plus aims to complete crucial objectives that will enhance the functionality of the GastroPlus software. This includes implementing novel product-particle size distribution (P-PSD) methodologies and sophisticated food effect modeling features, empowering researchers to better develop drug products and reduce animal study dependencies.

Empowering Researchers with Innovative Tools

In an era where precision is paramount, Dr. Xavier Pepin, Vice President of PBPK R&D at Simulations Plus, emphasized the importance of this partnership. He stated that collaborating with a consortium comprised of pharmaceutical innovators is a significant step in recognizing the integral role that GastroPlus plays across the drug development landscape. This initiative is not just about innovation—it's about enabling researchers to tackle complex pharmaceutical challenges with improved accuracy and efficiency.

Collaboration and Beta Testing for System Enhancements

A key element of this collaboration is the continuous delivery of beta versions of the enhanced GastroPlus platform to members of the ETC for extensive testing and feedback. This process aims to refine the software further and ensure that it meets the needs of the industry before release. Simulations Plus will retain ownership of intellectual property that arises from this collaboration, ensuring that any future enhancements remain grounded in their expertise in physiologically based pharmacokinetics (PBPK) and pharmacodynamics (PBBM) science.

About the Enabling Technologies Consortium

The Enabling Technologies Consortium serves as a collaborative hub for pharmaceutical and biotechnology firms. Their mission is to advance enabling technologies that enhance drug discovery and development processes. By fostering a pre-competitive environment, ETC enables member organizations to collectively address challenges and innovate solutions that are beneficial across the pharmaceutical landscape. The consortium is committed to publishing results and making advancements widely accessible to enhance the drug development process.

About Simulations Plus, Inc.

With a rich history spanning over 25 years, Simulations Plus, Inc. leads the biopharma industry in delivering cutting-edge biosimulation software and consulting services. Their offerings assist in drug discovery, development, and regulatory submissions while employing innovative techniques like artificial intelligence and machine learning to enhance process efficiencies. The company’s commitment to providing state-of-the-art technology positions it as an essential partner for pharmaceutical and regulatory organizations worldwide.

Environmental, Social, and Governance Initiatives

Simulations Plus is dedicated to making a positive impact through its Environmental, Social, and Governance (ESG) efforts. They are proactively working on initiatives that promote sustainability and corporate responsibility. To learn more about their ongoing ESG initiatives, visitors are encouraged to check their website for insights on current priorities and developments.

Frequently Asked Questions

What is the purpose of the collaboration between Simulations Plus and ETC?

The partnership aims to enhance the GastroPlus platform's capabilities in drug development, particularly focusing on oral drug delivery methodologies.

How will this collaboration affect the GastroPlus software?

The software is set to receive upgrades, including improvements to its predictive models and new methodologies that enhance research capabilities.

Who are the members of the Enabling Technologies Consortium?

Members include leading organizations in the pharmaceutical and biotechnology sectors, all committed to pioneering advancements in drug development.

What is the significance of the updates to the GastroPlus platform?

The updates will provide researchers with advanced tools to facilitate drug product development and streamline regulatory processes, reducing reliance on animal studies.

How does Simulations Plus ensure continuous innovation?

By retaining ownership of any developed intellectual property, Simulations Plus guarantees that enhancements to their platform reflect their ongoing commitment to innovation in the industry.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.